ImmunityBio (IBRX) to Release Quarterly Earnings on Monday

ImmunityBio (NASDAQ:IBRX) will likely be posting its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $43.0690 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. On average, analysts expect ImmunityBio to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ImmunityBio Price Performance

IBRX stock traded up $0.40 during midday trading on Monday, hitting $7.51. The stock had a trading volume of 3,509,223 shares, compared to its average volume of 32,021,395. The business has a 50-day moving average of $8.13 and a two-hundred day moving average of $5.06. ImmunityBio has a 52-week low of $1.83 and a 52-week high of $12.43. The firm has a market cap of $7.72 billion, a price-to-earnings ratio of -19.78 and a beta of 0.02.

Insider Activity at ImmunityBio

In other news, Director Barry J. Simon sold 165,000 shares of ImmunityBio stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the sale, the director owned 2,925,821 shares in the company, valued at $29,989,665.25. This trade represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Insiders have sold 275,000 shares of company stock worth $2,934,500 in the last ninety days. Insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Several large investors have recently bought and sold shares of the business. Mariner LLC increased its position in ImmunityBio by 10.5% during the fourth quarter. Mariner LLC now owns 17,814 shares of the company’s stock valued at $35,000 after acquiring an additional 1,689 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in ImmunityBio by 4.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 75,776 shares of the company’s stock worth $150,000 after acquiring an additional 3,280 shares during the period. Engineers Gate Manager LP lifted its stake in ImmunityBio by 15.3% in the fourth quarter. Engineers Gate Manager LP now owns 26,968 shares of the company’s stock worth $53,000 after acquiring an additional 3,578 shares during the period. Creative Planning lifted its stake in ImmunityBio by 9.2% in the second quarter. Creative Planning now owns 62,028 shares of the company’s stock worth $164,000 after acquiring an additional 5,231 shares during the period. Finally, Xponance LLC raised its holdings in ImmunityBio by 29.4% in the fourth quarter. Xponance LLC now owns 23,168 shares of the company’s stock worth $46,000 after purchasing an additional 5,270 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on IBRX shares. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. BTIG Research assumed coverage on shares of ImmunityBio in a research note on Thursday, March 12th. They set a “buy” rating and a $13.00 target price for the company. D. Boral Capital reissued a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a report on Tuesday, April 21st. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. Finally, HC Wainwright increased their target price on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.40.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.